Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

ABBV

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

ABBV

AI Research Report

Powered by Claude

Ready to analyze ABBV

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

C+
Stonvex Quant Grade
50.0/ 100
Rank-normalised composite of 6 factors, updated every 60 seconds.
Volume
C+
50 / 100

Today's volume vs prior session average.

Volatility
C+
50 / 100

Absolute daily price move vs peers.

News Flow
C+
50 / 100

24h article count relative to the universe.

Sentiment
C+
50 / 100

AI-classified polarity of recent news.

Dollar Flow
C+
50 / 100

Today's dollar turnover (volume × VWAP).

Relative Strength
C+
50 / 100

Signed daily return vs the rest of the universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Similar stocks

View all Biotech →
MRNA
Moderna
$42.80
+5.29%
LLY
Eli Lilly
$810.50
+2.30%
UNH
UnitedHealth
$485.20
-2.51%
NVO
Novo Nordisk
—
—
BNTX
BioNTech
—
—
REGN
Regeneron
—
—
Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

whgksdhr1111@naver.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

AbbVie Inc

AbbVie Inc

Biotechnology·NEW YORK STOCK EXCHANGE, INC.·US·IPO 2013-01-02

Analyst Consensus

Buy
Based on 39 analysts
Period: 2026-04-01
28 Buy (72%)11 Hold (28%)0 Sell (0%)
Rating Distribution
Strong Buy
7
Buy
21
Hold
11
Sell
0
Strong Sell
0
Trend
2026-04
28/11/0
2026-03
27/12/0
2026-02
25/12/0
2026-01
26/11/0

Factor Grades

View details →
C
Overall score: 47/100
D+
Valuation
C-
Growth
B+
Profitability
D+
Momentum
C-
Financial Health
NEW YORK STOCK EXCHANGE, INC.After-hours
AbbVie Inc
Biotechnology
$210.26
$3.79 (+1.84%)
After-hrs · vs prev close $206.47
Open
$204.80
Prev close
$206.47
Day range
$204.06 – $210.42
52W range
$164.97 – $244.81
Mkt cap
$365.20B
P/E
86.3
EPS
$2.38
Beta
0.33

Fundamentals

Valuation
Market Cap
$365.20B
P/E (TTM)
86.27S&P avg ~22
P/S (TTM)
5.96S&P avg ~2.8
P/B
261.01S&P avg ~4.5
P/FCF
20.46S&P avg ~26
EPS (TTM)
$2.38
Book/sh
$0.80
Cash/sh
$2.97
Profitability
Gross Margin
71.62%
avg ~45%
Operating Margin
24.65%avg ~15%
Net Margin
6.91%avg ~12%
ROE
95.59%avg ~18%
ROA
3.12%avg ~7%
ROI
5.66%
Payout Ratio
275.84%
FCF/sh
—
Growth & Health
Rev Growth YoY
8.57%
Rev Growth 5Y
5.95%
EPS Growth YoY
-1.30%
EPS Growth 5Y
-2.88%
Current Ratio
—
Quick Ratio
0.41
Debt/Equity
—
LT Debt/Eq
—
Trading & Dividends
Beta
0.33
52W High
$244.81
52W Low
$164.97
Avg Vol (10D)
6.25M
Avg Vol (3M)
6.71M
Div Yield
3.35%
Div/sh (TTM)
—
Analyst
Buy (39)
Price Performance
5D+0.05%
MTD-5.07%
3M-7.88%
6M-10.30%
YTD-9.64%
1Y+18.52%
📅 Earnings in 15d (Apr 29)
  • Yahoo·5h ago

    Three Stocks That May Be Trading Below Estimated Value In April 2026

    Over the last 7 days, the United States market has risen by 4.2%, contributing to a 29% increase over the past year, with earnings forecasted to grow by 16% annually. In this environment of growth, identifying stocks that may be trading below their estimated value can offer investors potential opportunities for capitalizing on future gains.

  • Yahoo·5h ago

    Could AbbVie Crash Lilly's Weight‑Loss Party?

    AbbVie is making progress in this market, but it is still far behind the leader.

  • Yahoo·7h ago

    Revolution Medicines Facing Further Upside After Daraxonrasib's Results, RBC Says

    Revolution Medicines (RVMD) has several paths toward additional upside on potential M&A deals and a

  • SeekingAlpha·7h ago

    Revolution Medicines: 'Strong Buy' On Daraxonrasib Win And Expansions Underway

    Read the latest analysis on Revolution Medicines (RVMD) stock here.

  • Yahoo·10h ago

    Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

    Allergan Aesthetics, an AbbVie company (NYSE: ABBV) has teamed up with New York-based entrepreneur and television personality, Erin Lichy. Lichy is opening up about her recent breast augmentation with market-leading Natrelle® breast implants in an effort to promote transparency and normalize conversations around aesthetic procedures. As a mom of four, and after years of breastfeeding, Lichy's decision to pursue breast augmentation is a part of her personal journey towards renewed body positivity

  • Yahoo·11h ago

    April 2026's Noteworthy Stocks Possibly Priced Below Estimated Worth

    The United States market has shown robust growth, rising 4.2% over the last week and 29% over the past year, with earnings projected to increase by 16% annually. In such a thriving environment, identifying stocks that may be undervalued requires careful consideration of their potential for growth relative to current market conditions.

  • Yahoo·11h ago

    Johnson & Johnson (JNJ) Surpasses Q1 Earnings and Revenue Estimates

    Johnson & Johnson (JNJ) delivered earnings and revenue surprises of +1.07% and +2.63%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

  • Yahoo·11h ago

    2 S&P 500 Stocks with Solid Fundamentals and 1 We Brush Off

    The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.

  • View all news →
⚠️
Dilution risk detected

4 offering-related filings in the last 60 filings. Latest: 424B5 on 2026-02-26. View all →

Recent insider activity

View all →
  • 4Insider transaction
    12d ago
  • 4Insider transaction
    12d ago
  • 4Insider transaction
    12d ago
  • 4/AInsider transaction
    Mar 11
  • 4Insider transaction
    Mar 6